United States
Securities and Exchange Commission
Washington, D.C. 20549
_______________________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 27, 2010
CytoGenix, Inc.
(Exact name of registrant as specified in its charter)
0-26807
(Commission File Number)
| Nevada | 76-048409 |
| | |
| (State or other jurisdiction of incorporation) | (IRS Employer Identification No.) |
| | |
| | |
| 710 N. Post Oak Road, Suite 410, Houston, TX | 77024 |
| (Address of principal executive offices) | (Zip Code) |
(713) 780-0806
Registrant’s telephone number, including area code
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.
On October 27, 2010, Cytogenix, Inc ("CYGX.PK") (the “Company”) received a letter of resignation from Lex M. Cowsert. Dr. Cowsert resigned his position as Chief Executive Officer, President and as a Director effective immediately.
The Company has appointed Cy Stein, M.D., Ph.D. to serve as President and Chief Executive Officer until a permanent replacement can be found.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
Exhibits.
| | |
| 99.1 | Letter of Resignation |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | |
| | |
| Date: November 16, 2010 | CytoGenix, Inc. |
| | By /s/ Steven M. Plumb Steven M. Plumb, Chief Financial Officer |
